Clinical trials
Patient Safety clinical trials
Below are recruiting patient safety clinical trials, each written for real people, not researchers. We’re tracking 1,354 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07121413RecruitingPhase 2
Testing SV001 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
ChengduAges 40 years+ - NCT07126782RecruitingEarly Phase 1
Gene-edited immune cells for AML after transplant
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
BeijingAges 18 years+ - NCT07156773RecruitingPhase 2
Nasal spray for Parkinson's off episodes
This study tests a new nasal spray called XJN010 for people with Parkinson's who have 'off' episodes—times when their regular medication wears off and symptoms come back. The goal is to see if the spray can safely and effectively help during those periods.
Guangzhou, GuangdongAges 30–85 - NCT07185880RecruitingPhase 1/Phase 2
Testing MT-125 for newly diagnosed glioblastoma
This trial tests a new drug called MT-125 for people with a specific type of brain cancer called glioblastoma (GBM) that is IDH wildtype and MGMT unmethylated. The study will see if MT-125 is safe and tolerable, and how well it works.
Phoenix, ArizonaAges 18 years+ - NCT07205315RecruitingEarly Phase 1
Testing GT801 cell therapy for blood cancer and AIHA
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
Zhengzhou, HenanAges 18–75 - NCT07208591RecruitingPhase 3
Test of an experimental drug for severe viral lung infection (ARDS)
This study tests an experimental drug (STSA-1002) for people with severe breathing problems caused by a viral infection. It aims to see if the drug can help improve oxygen levels and reduce the need for a breathing machine.
Beijing, Beijing MunicipalityAges 18–85 - NCT07251023RecruitingPhase 3
Testing a new drug for Alzheimer's dementia
This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.
Kazan'Ages 60–90 - NCT07252323Recruiting
Carbon ion radiotherapy for liver cancer after TARE
This trial tests a new type of radiation therapy (carbon ion radiotherapy) for people with liver cancer that has not been fully controlled after prior TARE treatment. It aims to see if it is safe and effective for treating the remaining or returning cancer.
SeoulAges 20 years+ - NCT07263139RecruitingPhase 2
Testing AGP100 for CPVT heart condition
This trial tests a new drug called AGP100 for people with CPVT, a genetic heart condition that causes dangerous heartbeats during exercise. The goal is to see if AGP100 can safely reduce these abnormal heart rhythms.
OsloAges 18–75 - NCT07279194RecruitingPhase 3
Study of HDM1005 for weight loss in Chinese adults without diabetes
This trial tests a new medication, HDM1005, to help people with obesity or overweight who do not have diabetes lose weight. It is for Chinese adults who have a high body mass index (BMI) or a BMI above 24 with weight-related health problems like high blood pressure or fatty liver.
ShanghaiAges 18 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07367100Recruiting
Testing a new clot-removal catheter for stroke
This study tests a special catheter (a thin tube) designed to remove blood clots from large arteries in the brain during a stroke. The goal is to see if it is safe and effective at restoring blood flow.
EdegemAges 18–90 - NCT07399704RecruitingPhase 2
Testing a new drug for two rare brain diseases
This trial is for people with Niemann-Pick type C or GM2 gangliosidosis who are already on or have been in a related study. It tests a new drug called Nizubaglustat to see if it is safe and works better than current treatments.
Água Verde, CuritibaAges 12 years+ - NCT07404033RecruitingPhase 1
Testing a lotion for mild to moderate dandruff rash
This trial tests a new lotion for people with mild to moderate seborrheic dermatitis (a common skin condition causing red, scaly patches on the scalp, face, or chest). The study checks safety and how well the lotion works.
Suzhou, JiangsuAges 18–65 - NCT07672756RecruitingPhase 1
Testing PL54 injection for adults with PKU
This study tests a new injection called PL54 to see if it is safe and tolerable for adults with phenylketonuria (PKU), a condition where the body cannot break down an amino acid called phenylalanine. It is designed for people with high blood phenylalanine levels and may offer a new treatment option.
Hefei, AnhuiAges 18–55 - NCT07490262RecruitingPhase 2/Phase 3
Immunotherapy combo for advanced liver cancer as first treatment
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hefei, AnhuiAges 18–75 - NCT07529782RecruitingPhase 1
Safety and Efficacy of HDP-101 in Relapsed or Refractory Multiple Myeloma
This trial tests a new drug called HDP-101 in patients with multiple myeloma that has come back or stopped responding to previous treatments. The study aims to find the safest and most effective dose and to see if this drug can help control the cancer.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT07579234RecruitingPhase 3
New drug F182112 for hard-to-treat multiple myeloma
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
TianjingAges 18 years+ - NCT07634991RecruitingPhase 4
N-acetyl Cysteine for Diabetic Eye Disease
This study tests whether a supplement called N-acetyl cysteine can help slow or improve mild to moderate diabetic eye disease (diabetic retinopathy). The goal is to see if it's safe and effective for people with type 2 diabetes.
CairoAges 18–70 - NCT07259356Enrolling by invitation
Blood-flow-restriction training for hemophilia patients
This trial tests whether a special type of exercise that limits blood flow is safe and possible for people with hemophilia. It might help strengthen muscles without causing joint bleeds.
Bonn, North Rhine-WestphaliaAges 18 years+ - NCT07077811Enrolling by invitation
Pulsed field ablation for heart failure with preserved pumping strength
This trial tests a new procedure called pulsed field ablation for people who have both persistent atrial fibrillation and a type of heart failure (HFpEF). It aims to see if this ablation safely helps control the heart rhythm.
Nantong, JiangsuAges 18–80 - NCT06807515Enrolling by invitation
Safety study of FL Nourish supplement for cancer survivors in remission
This study is testing whether a natural herbal supplement called FL Nourish Capsules is safe for people who have had cancer and are now in remission. It focuses on those with a Traditional Chinese Medicine pattern of Qi deficiency and Blood stasis, which may cause tiredness and poor circulation.
Singapore, SGAges 21–80 - NCT06452823Enrolling by invitation
Catheter ablation for atrial fibrillation with stable thyroid
This trial tests whether doing a heart procedure (catheter ablation) is safe and works well for people with atrial fibrillation whose thyroid hormone levels are stable. It aims to help people with both conditions get the best treatment.
Jiaxing, ZhejiangAges 45–75 - NCT07136181RecruitingPhase 1/Phase 2
Study of NBM-BMX for advanced uveal melanoma that has spread
This trial tests a new oral drug, NBM-BMX, for people with metastatic uveal melanoma (melanoma of the eye that has spread). It aims to see if the drug is safe and effective. You may join if you have already tried some treatments, including tebentafusp if you are HLA-A*02:01 positive.
Scottsdale, ArizonaAges 18 years+
Hear when a new Patient Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient safety?
- Yes. Clin2 currently lists 1,354 recruiting patient safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.